Ujvira 100 mg Injection Ujvira 100 mg Injection contains trastuzumab emtansine, a targeted anticancer medicine used primarily for HER2-positive breast cancer. It combines a monoclonal antibody that targets HER2-positive cancer cells with a chemotherapy component, helping deliver the anticancer drug directly to the targeted cells. Ujvira is administered as an intravenous infusion under the supervision of a qualified healthcare professional.

Effects & Benefits Targets HER2-positive cancer cells. Helps slow or stop the growth of HER2-positive breast cancer cells. Used in eligible patients with HER2-positive breast cancer. Provides targeted delivery of the chemotherapy component to HER2-expressing cancer cells. May be used in appropriate patients with early or metastatic HER2-positive breast cancer according to the oncologist's treatment plan.